Correction: Nanosphere Eyes FDA OK for Plavix Metabolism, Troponin Tests | GenomeWeb

The story has been updated to correct revenue estimates Nanosphere's CFO provided at the conference for tests in the company's pipeline.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nanosphere CFO Roger Moody told investors Wednesday at the 2011 Jefferies Global Healthcare Conference that the company has filed for US marketing clearance for a companion diagnostic test for assessing Plavix (clopidogrel) metabolism.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.